Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 1;152(3):274-282.
doi: 10.1001/jamasurg.2016.4749.

Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer

Affiliations

Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer

Reshma Jagsi et al. JAMA Surg. .

Abstract

Importance: Contralateral prophylactic mastectomy (CPM) use is increasing among women with unilateral breast cancer, but little is known about treatment decision making or physician interactions in diverse patient populations.

Objective: To evaluate patient motivations, knowledge, and decisions, as well as the impact of surgeon recommendations, in a large, diverse sample of patients who underwent recent treatment for breast cancer.

Design, setting, and participants: A survey was sent to 3631 women with newly diagnosed, unilateral stage 0, I, or II breast cancer between July 2013 and September 2014. Women were identified through the population-based Surveillance Epidemiology and End Results registries of Los Angeles County and Georgia. Data on surgical decisions, motivations for those decisions, and knowledge were included in the analysis. Logistic and multinomial logistic regression of the data were conducted to identify factors associated with (1) CPM vs all other treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS). Associations between CPM receipt and surgeon recommendations were also evaluated. All statistical models and summary estimates were weighted to be representative of the target population.

Main outcomes and measures: Receipt of CPM was the primary dependent variable for analysis and was measured by a woman's self-report of her treatment.

Results: Of the 3631 women selected to receive the survey, 2578 (71.0%) responded and 2402 of these respondents who did not have bilateral disease and for whom surgery type was known constituted the final analytic sample. The mean (SD) age was 61.8 (12) years at the time of the survey. Overall, 1301 (43.9%) patients considered CPM (601 [24.8%] considered it very strongly or strongly); only 395 (38.1%) of them knew that CPM does not improve survival for all women with breast cancer. Ultimately, 1466 women (61.6%) received BCS, 508 (21.2%) underwent UM, and 428 (17.3%) received CPM. On multivariable analysis, factors associated with CPM included younger age (per 5-year increase: odds ratio [OR], 0.71; 95% CI, 0.65-0.77), white race (black vs white: OR, 0.50; 95% CI, 0.34-0.74), higher educational level (OR, 1.69; 95% CI, 1.20-2.40), family history (OR, 1.63; 95% CI, 1.22-2.17), and private insurance (Medicaid vs private insurance: OR, 0.47; 95% CI, 0.28-0.79). Among 1569 patients (65.5%) without high genetic risk or an identified mutation, 598 (39.3%) reported a surgeon recommendation against CPM, of whom only 12 (1.9%) underwent CPM, but among the 746 (46.8%) of these women who received no recommendation for or against CPM from a surgeon, 148 (19.0%) underwent CPM.

Conclusions and relevance: Many patients consider CPM, but knowledge about the procedure is low and discussions with surgeons appear to be incomplete. Contralateral prophylactic mastectomy use is substantial among patients without clinical indications but is low when patients report that their surgeon recommended against it. More effective physician-patient communication about CPM is needed to reduce potential overtreatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Allison W. Kurian has received research funding for work performed outside of the current study from Myriad Genetics, Invitae, Ambry Genetics, GeneDx, and Genomic Health. The remaining authors have no conflict of interest to report.

Figures

Figure 1
Figure 1. Strength of consideration of CPM by risk for contralateral primary cancer
This figure depicts the proportion of patients sampled who reported consideration of CPM, along with the strength of that consideration, by risk groups defined using age, family history, and biologic subtype, derived from the contemporaneous NCCN guidelines for assessment of genetic risk.
Figure 2
Figure 2. Motivations for CPM receipt
The 428 women in our sample who chose CPM were asked the importance of various factors in their decision to have the procedure. This figure depicts the distribution of their responses for wanting reconstruction to change the size of the breasts, having a positive BRCA 1 or 2 test result, having a family history of breast cancer, wanting reconstruction to best match the breasts, age, and wanting peace of mind.
Figure 3
Figure 3. Receipt of CPM by surgeon recommendation
This figure demonstrates the rates of CPM receipt among patients reporting a surgeon recommendation against it, no surgeon recommendation for nor against it, and surgeon recommendation for it.

Comment in

Similar articles

Cited by

References

    1. Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. Journal of the National Cancer Institute. 2014;106(8) - PubMed
    1. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(16):2158–2164. - PubMed
    1. Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL. The Angelina effect: immediate reach, grasp, and impact of going public. Genetics in medicine : official journal of the American College of Medical Genetics. 2014;16(7):516–521. - PubMed
    1. Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Annals of surgical oncology. 2009;16(10):2697–2704. - PubMed
    1. Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Annals of surgical oncology. 2009;16(10):2691–2696. - PubMed

MeSH terms